By all means stick to your guns, there is nothing wrong with others critiquing what's clearly written right there in the report. The reality is the share price will ultimately follow the risk vs value, and there's always hope that the share price rises (I hope it does in particular for those wishing to sell out at a lesser loss).
You can't shrink your way to greatness. They revenue spike is a one off, there is no future revenue attached to the trial. They reduced costs because the survival of the business requires it too.
If they can land some big clinical trials this year then they will look interesting.
Add to My Watchlist
What is My Watchlist?
